U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda ...

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at ...

A domestic research team has succeeded in converting methane, a major greenhouse gas, into eco-friendly bio-materials using a biofoundry. On October ...

Patent number 3,174,137, which is titled Gut Microbiota Bioactivated PDE4 Inhibitor Precursors, encompasses the composition ...

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical ...

(PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patientsFavorable safety and PK profile, with encouraging activity, demonstrate a ...

CN Bio, a leading provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix® Core.

CN Bio in Cambridge, which provides benchtop Organ-on-a-chip (OOC) solutions to accelerate drug discovery and development, ...